z-logo
Premium
Increased expression of hyaluronic acid binding protein 1 is correlated with poor prognosis in patients with breast cancer
Author(s) -
Chen YanBo,
Jiang ChuanTao,
Zhang GuoQiang,
Wang JinSong,
Pang Da
Publication year - 2009
Publication title -
journal of surgical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.201
H-Index - 111
eISSN - 1096-9098
pISSN - 0022-4790
DOI - 10.1002/jso.21329
Subject(s) - breast cancer , immunohistochemistry , medicine , hyaluronic acid , metastasis , cancer , oncology , multivariate analysis , pathology , cancer research , anatomy
Background and Objectives Hyaluronic acid binding protein 1 (HABP1), a family of proteins interacting with hyaluronan (HA), had been associated with cell adhesion and tumor invasion. The aim of this study was to investigate the correlation between clinicopathologic factors and patient survival time with the expression of HABP1 in breast cancer patients. Methods Expression of HABP1 mRNA and protein were detected with real‐time quantitative PCR and immunohistochemical staining in 63 breast cancer and non‐cancerous matched tissues. Results The mRNA expression level of HABP1 was unrelated to the patient's age, tumor size, histological grade, TNM stage. However, it proved to be positively related to axillary nodes metastasis ( P  = 0.008). Furthermore, it was shown that the survival rate of patients with low HABP1 expression was significantly higher than that of patients with high HABP1 expression ( P  = 0.025). Multivariate analysis revealed that HABP1 mRNA expression level was a significant factor for predicting prognosis ( P  = 0.022). The immunohistochemistry results showed that the expression level of HABP1 in breast cancer cells was higher than that in normal breast cells. Conclusion HABP1 might be an independent predictive factor for breast cancer prognosis and up‐regulation of HABP1 might play an important role in the metastasis of breast cancer. J. Surg. Oncol. 2009;100:382–386. © 2009 Wiley‐Liss, Inc.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here